3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Leukemia, Myeloid, Acute
12
Myelodysplastic Syndromes
6
Triple Negative Breast Neoplasms
1
Systemic Mastocytosis With an Associated Hematologic Neoplasm
1
Neurofibrosarcoma
1
Neuroendocrine Tumors
1
Myeloproliferative Disorders
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Hodgkin Disease
1
GATA2 Deficiency
1
Cytopenia
1
Central Nervous System Neoplasms
1
BRCA1 Mutation
1
Accelerated Phase Myeloproliferative Neoplasm
1
Interventions
lutetium Lu 177 dotatate
10
Everolimus
5
lanreotide
4
gallium Ga 68 dotatate
4
Nivolumab
4
Magnetic Resonance Spectroscopy
4
177Lu-octreotide, DOTA(0)-Tyr(3)-
4
olaparib
3
Temozolomide
3
Somatostatin
3
Capecitabine
3
surufatinib
2
pembrolizumab
2
copper dotatate CU-64
2
cabozantinib
2
amino-acid, glucose, and electrolyte solution
2
Specimen Handling
2
Octreotide
2
Lutetium-177
2
Lutetium
2
Injections
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
talazoparib
1
sintilimab
1
repotrectinib
1
lenvatinib
1
guarana powder
1
gadoteridol
1
gadoterate meglumine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neuroendocrine Tumors
×
decitabine and cedazuridine drug combination
×
Clear all
NCT05178693
2025-11-24
LANTana
Imperial College London
Phase 1
Recruiting
27 enrolled